AlzChem Group AG/€ACT

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About AlzChem Group AG

AlzChem Group AG operates within the chemical industry, focusing on the production and distribution of specialty chemicals. The company offers a wide range of products, including nitrile and guanidine derivatives, which are used in various applications such as agriculture, pharmaceuticals, and renewable energy. Headquartered in Trostberg, Germany, AlzChem has a strong foundation in the region but exports its products globally. The company's strategic positioning leverages its specialized product offerings and research capabilities, enabling it to serve niche markets with high-value solutions. AlzChem's history includes a rich legacy of chemical expertise and innovation that began at its founding.

Ticker

€ACT
Sector

Primary listing

XETRA

Employees

1,647

AlzChem Group AG Metrics

BasicAdvanced
€1.4B
24.82
€5.71
0.80
€1.80
1.27%

Bulls say / Bears say

In Q2 2025, AlzChem’s revenue climbed nearly 5% year-on-year to €142.9 million and EBITDA rose nearly 8% to €29.1 million, reflecting robust demand for higher-margin specialty chemicals (MarketScreener).
In FY 2024, AlzChem achieved a record EBITDA of €105.3 million, a 29.4% increase year-on-year, with the specialty chemicals segment driving margin expansion to 19.0% (AlzChem Corporate News).
The expansion of nitroguanidine production capacity in Germany remains on schedule and within budget, and site selection for a U.S. facility is underway, supporting future volume growth (MarketScreener).
In the first half of 2025, sales in the Basics & Intermediates segment fell 14% to €78.2 million and segment EBITDA declined to €1.3 million due to weak European steel demand and intensified price competition from Chinese suppliers (WebDisclosure).
After reaching an all-time high near €167 in mid-2025, AlzChem’s stock slid about 17% as profit-taking set in, underscoring volatility despite a more than doubling of the share price year-to-date (MarketScreener).
Operating cash flow in H1 2025 was buoyed by €51.0 million of customer grants for capacity expansion, and free cash flow declined from €51.4 million to €30.7 million, highlighting dependence on non-operational cash receipts (Finanzen.ch).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €ACT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs